Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement

杭州啓明醫療器械股份有限公司

Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

VOLUNTARY ANNOUNCEMENT
SUBMISSION OF CE MDR MARKING APPLICATION FOR THE CARDIOVALVE TRICUSPID VALVE REPLACEMENT

This announcement is issued by Venus Medtech (Hangzhou) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest information regarding the Group's latest business development and the research and development progress of new products.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Group has recently formally submitted all application materials for CE MDR marking to a European Notified Body in respect of the Cardiovalve transcatheter tricuspid valve replacement system (the "**Cardiovalve System**").

Cardiovalve System is a transcatheter interventional replacement product designed for the treatment of both mitral regurgitation and tricuspid regurgitation. Compared with similar products, Cardiovalve System's transfemoral approach significantly enhances treatment safety. Its large annulus design, up to 55 mm, makes the product suitable for approximately 95% of the patient. In addition, its unique short frame design effectively reduces the risk of left ventricular outflow tract obstruction. Cardiovalve System is easy to operate, safe, highly repeatable, and can be completed in three steps: positioning, anchoring and release.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Group cannot guarantee that the Cardiovalve System will ultimately be successfully marketed.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Venus Medtech (Hangzhou) Inc.
Mr. Lim Hou-Sen (Lin Haosheng)
Executive Director

Hangzhou, December 24, 2025

As at the date of this announcement, the executive Directors are Mr. Lim Hou-Sen (Lin Haosheng), Mr. Liqiao Ma and Ms. Meirong Liu; the non-executive Directors are Mr. Ao Zhang and Mr. Wei Wang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Chi Wai Suen and Mr. John Junhua Gu.